Европейски съюз - български - EMA (European Medicines Agency)

pfizer europe ma eeig - dacomitinib монохидрат - Карцином, недребноклетъчен белодроб - Антинеопластични средства - vizimpro, като монотерапии, се предписват за първа линия на лечение при възрастни пациенти с локално-разпространена или метастатичен немелкоклеточного рак на белия дроб (НМРЛ) с епидермален фактор на растежа (egfr) спомагателни мутации.

България - български - БАБХ (Българска агенция по безопасност на храните)

richter pharma ag - Прокаина хидрохлорид, доза адреналин гидротартрат - инжекционна суспензия - 40 mg/ml; 0.036 mg/ml - говеда, коне, овце, прасета

Европейски съюз - български - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - Белодробна болест, хронична обструктивна болест - Лекарства за обструктивна заболявания на дихателните пътища, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Европейски съюз - български - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - Множествена Склероза, Рецидивно-Ремиттирующее - Имуносупресори - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Европейски съюз - български - EMA (European Medicines Agency)

mylan ireland limited - абаратер ацетат - Простатни неоплазми - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Европейски съюз - български - EMA (European Medicines Agency)

krka, d.d., novo mesto - абаратер ацетат - Простатни неоплазми - Ендокринна терапия - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Европейски съюз - български - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - Белодробна болест, хронична обструктивна болест - Лекарства за обструктивна заболявания на дихателните пътища, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Европейски съюз - български - EMA (European Medicines Agency)

accord healthcare s.l.u. - relugolix - Простатни неоплазми - Ендокринна терапия - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Европейски съюз - български - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - Простатни неоплазми - Ендокринна терапия - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Европейски съюз - български - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - Новообразувания На Простатата, Кастраци-Упорит - Антинеопластични средства - treatment of adult patients with prostate cancer.